TABLE 1.

Myo/pericarditis occurrence per million adolescents following BNT162b2 vaccination doses 1 and 2, by age and sex

Age and Dose	Number Vaccinated* as of 6/11/21	Females			Males
		Expected	Observed	Myo/pericarditis per Million Vaccinated (95% CI)	Expected	Observed	Myo/pericarditis per Million Vaccinated (95% CI)
12–15
Dose 1	3,669,373	1.35	0	0.0 (0.0‐0.2)	2.12	21	11.4 (7.09, 17.5)
Dose 2	1,233,021	1.35	8	13.0 (5.6, 25.6)	2.12	100	162.2 (132.0, 197.3)
16–17
Dose 1	2,943,756	1.35	2	1.4 (0.2, 4.9)	2.12	12	8.2 (4.21, 14.2)
Dose 2	2,085,725	1.35	13	12.5 (6.6, 21.3)	2.12	97	93.0 (75.4, 113.5)
12–17
Dose 1	6,613,129	1.35	2	0.6 (0.1, 2.2)	2.12	33	10.0 (6.9, 14.0)
Dose 2	3,318,746	1.35	21	12.7 (7.8, 19.3)	2.12	197	118.7 (102.7, 136.5)

^*Number vaccinated is divided by two to compute male and female rates per million.